Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: A phase I study

S. Toma, R. Palumbo, A. Comandone, C. Oliva, M. Vincenti, C. Bumma, R. Rosso

Research output: Contribution to journalArticle

Abstract

Background: There is evidence that continuous infusion allows the delivery of higher doses of a drug while reducing the incidence of neurologic and renal toxicity. To verify prior to phase II testing the feasibility of ambulatory treatment with high-dose ifosfamide/mesna by continuous infusion in adult solid tumours, the maximum tolerated dose (MTD) and the non-haematological dose-limiting toxicities for the achievement of 2 courses of therapy were determined. Patients and methods: Thirty-two patients with advanced solid rumours were given continuous-infusion ifosfamide, from 9 to 16 g/m2, over 4 consecutive days, with equidose mesna uroprotection and granulocyte colony-stimulating-factor support; courses were repeated every 3 weeks. Total dose/course was escalated by 1 g/m2, in cohorts of 3 to 5 patients until the MTD was determined. Results: At 16 g/m2, the dose-limiting toxicity was renal, with 2 of the 5 patients treated developing rend failure. Haematological toxicity was dose-related and significant at higher dosages, but generally surmountable. Ifosfamide at 15 g/m2/course with mesna uroprotection was identified as the MTD. Conclusions: The present study shows that high-dose continuous-infusion ifosfamide, administered by portable infusion pumps, is feasible in an ambulatory regimen, with acceptable non-haematological toxicity and good patient compliance.

Original languageEnglish
Pages (from-to)193-196
Number of pages4
JournalAnnals of Oncology
Volume6
Issue number2
Publication statusPublished - 1995

Keywords

  • Ambulatory setting
  • Continuous infusion
  • High-dose chemotherapy
  • Ifosfamide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Fingerprint Dive into the research topics of 'Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: A phase I study'. Together they form a unique fingerprint.

  • Cite this